Board Meeting Details

The meeting commenced at 12:30 PM and concluded at 3:45 PM on October 27, 2026.

Key Approvals

1. Unaudited Financial Results: Approved standalone and consolidated financial results for quarter and half year ended September 30, 2026.

2. Share Buyback Approval:

  • Buyback of up to 24,00,000 fully paid-up equity shares (1.47% of total paid-up equity capital)
  • Buyback price: ₹500 per equity share
  • Total offer size: ₹120.00 Crores (less than 10% of paid-up equity capital and free reserves as per March 31, 2026 audited financials)
  • Method: Tender Offer route under SEBI Buyback Regulations, 2018
  • Maximum buyback size excludes transaction costs, brokerage, fees, taxes, publication expenses, and other incidental expenses
  • Board may increase buyback price and decrease number of shares until one working day prior to record date, maintaining aggregate size
  • Promoters and promoter group indicated intention to participate
  • Record date fixed: November 13, 2026

Financial Results - Standalone (Rs. in lakhs)

Quarter Ended September 30, 2026:

  • Revenue from operations: 55,279
  • Other income: 1,862
  • Total income: 57,141
  • Total expenses: 50,788
  • Profit before tax: 6,353
  • Tax expense: 1,700
  • Profit for period: 4,769
  • Basic EPS: ₹2.93 (not annualized)

Half Year Ended September 30, 2026:

  • Revenue from operations: 1,20,789
  • Other income: 6,364
  • Total income: 1,27,153
  • Total expenses: 1,03,372
  • Profit before tax: 23,781
  • Tax expense: 5,670
  • Profit for period: 17,972
  • Basic EPS: ₹11.04 (not annualized)

Comparative Quarterly Performance:

  • Q2 FY27 Revenue: 55,279 vs Q1 FY27: 65,510 vs Q2 FY26: 46,174
  • Q2 FY27 Profit: 4,769 vs Q1 FY27: 13,202 vs Q2 FY26: 2,948

Financial Results - Consolidated (Rs. in lakhs)

Quarter Ended September 30, 2026:

  • Revenue from operations: 57,214
  • Other income: 1,784
  • Total income: 59,008
  • Total expenses: 52,467
  • Profit before tax: 6,541
  • Tax expense: 1,635
  • Profit for period: 4,906
  • Basic EPS: ₹3.01 (not annualized)

Half Year Ended September 30, 2026:

  • Revenue from operations: 1,23,983
  • Other income: 6,328
  • Total income: 1,30,311
  • Total expenses: 1,06,300
  • Profit before tax: 24,011
  • Tax expense: 5,856
  • Profit for period: 18,155
  • Basic EPS: ₹11.15 (not annualized)

Subsidiary Information

The consolidated results include:

1. FDC International Limited, UK (wholly owned)

2. FDC Inc., USA (wholly owned)

3. Fair Deal Corporation Pharmaceuticals SA (Pty) Ltd., South Africa (wholly owned)

Share Capital

Paid-up equity share capital: ₹1,628 lakhs (Face Value Re.1 each)

Pre-Buyback Shareholding Pattern (as of October 23, 2026)

  • Promoters: 69.66% (11,34,10,433 shares)
  • Public: 30.34% (4,93,99,651 shares)
  • Mutual Funds/UTI: 6.56%
  • FII/FPI: 1.53%
  • Resident Individuals: 17.17%
  • Non-Resident Individuals: 1.80%
  • Bodies Corporate: 2.25%
  • Others: 1.03%

Additional Information

  • The company has only one segment: "Pharmaceuticals"
  • Statutory Auditors (BSR & Co. LLP) issued unmodified limited review report